All Stories

  1. The Distribution of Average Pairwise Distances Among Human Pre-miRNAs for Disease Association Analysis
  2. Three-Dimensional Bioprinting and Rose-Inspired Medical Applications
  3. Forecasting Upper Bounds for Daily New COVID-19 Infections Using Tolerance Limits
  4. Distribution of microRNA Counts Across Human Chromosomes
  5. Medical Benefits and Polymer Applications of Grapes
  6. EWMA Control Chart Integrated with Time Series Models for COVID-19 Surveillance
  7. A Review of Nanotechnology in microRNA Detection and Drug Delivery
  8. Advantages of animal leather over alternatives and its medical applications
  9. Anti-NMDA Receptor Encephalitis, Human Papillomavirus, and microRNA
  10. Beneficial medicinal effects and material applications of rose
  11. The Potential of Collagen Treatment for Comorbid Diseases
  12. Tolerance limits for mixture‐of‐normal distributions with application to COVID‐19 data
  13. Biomaterials in Medical Applications
  14. The Human Pre-miRNA Distance Distribution for Exploring Disease Association
  15. microRNA pathological mechanisms between Parkinson's disease, Alzheimer's disease, glaucoma and macular degeneration
  16. The distance distribution of human microRNAs in MirGeneDB database
  17. Phylogenetic Tree Selection by Testing Substitution Number in Clade
  18. Exploring the Causal Effect of Constipation on Parkinson’s Disease Through Mediation Analysis of Microbial Data
  19. A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
  20. COVID−19, Anti-NMDA Receptor Encephalitis and MicroRNA
  21. microRNA Biomarkers in Clinical Study
  22. Multiple imputation confidence intervals for the mean of the discrete distributions for incomplete data
  23. A Review of the Effects of Collagen Treatment in Clinical Studies
  24. The Association between Migraine and Depression based on miRNA Biomarkers and Cohort Studies
  25. MicroRNAs, Multiple Sclerosis, and Depression
  26. Editorial: miRNAs and Neurological Diseases
  27. MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus
  28. Confidence intervals for the proportion of conformance
  29. Exploring the Association of Autism Spectrum Disorders and Constipation through Analysis of the Gut Microbiome
  30. Phylogenetic analysis of microRNA biomarkers for amyotrophic lateral sclerosis
  31. The Generalized Bayes Method for High-Dimensional Data Recognition with Applications to Audio Signal Recognition
  32. MicroRNA, Diabetes Mellitus and Colorectal Cancer
  33. The Association between Depression and Gastroesophageal Reflux based on Phylogenetic Analysis of miRNA Biomarkers
  34. <p>Exploring Diversity of COVID‑19 Based on Substitution Distance</p>
  35. Monitoring Change Points by a Sign Change Method
  36. MicroRNAs and Apoptosis in Colorectal Cancer
  37. Constructing exact tolerance intervals for the exponential distribution based on record values
  38. Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
  39. Logistic Regression Method for Ligand Discovery
  40. Exact two‐sided tolerance interval controlling tail proportions for sample variances
  41. Anti-NMDA Receptor Encephalitis, Vaccination and Virus
  42. Vaccines and Neurological Disease
  43. Phylogenetic Analysis to Explore the Association Between Anti-NMDA Receptor Encephalitis and Tumors Based on microRNA Biomarkers
  44. Tolerance interval for the mixture normal distribution
  45. Exploring MicroRNA Biomarkers for Parkinson’s Disease from mRNA Expression Profiles
  46. How can we identify Amyotrophic Lateral Sclerosis with blood test?
  47. A protocol for investigating the association of vaccination and anti-NMDA receptor encephalitis
  48. Constructing Tolerance Intervals for the Number of Defectives Using Both High- and Low-Resolution Data
  49. Why ALS is often associated with cancers?
  50. A control chart for the lognormal standard deviation
  51. Anti-NMDA Receptor Encephalitis and Vaccination
  52. Predicting MicroRNA Biomarkers for Cancer Using Phylogenetic Tree and Microarray Analysis
  53. On the monitoring of mixture simple linear profiles
  54. Efficacies of treatments for anti-NMDA receptor encephalitis
  55. Corrigendum to “Variance estimation for nucleotide substitution models” [Mol. Phylogenet. Evol. 90 (2015) 97–103]
  56. Multivariate control charts based on the James–Stein estimator
  57. Variance estimation for nucleotide substitution models
  58. Control Charts for the Lognormal Mean
  59. Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
  60. Correction: Investigating microRNA-Target Interaction-Supported Tissues in Human Cancer Tissues Based on miRNA and Target Gene Expression Profiling
  61. Investigating microRNA-Target Interaction-Supported Tissues in Human Cancer Tissues Based on miRNA and Target Gene Expression Profiling
  62. Shrinkage regression-based methods for microarray missing value imputation
  63. RRSM with a data-dependent threshold for miRNA target prediction
  64. Bayesian Ranking Responses in Multiple-Response Questions
  65. Protein-specific Scoring Method for Ligand Discovery
  66. Confidence intervals for a bounded mean in exponential families
  67. Phylogenetic tree selection by the adjustedk-means approach
  68. Human microRNA target identification by RRSM
  69. Yeast cell cycle transcription factors identification by variable selection criteria
  70. Confidence intervals for the substitution number in the nucleotide substitution models
  71. Constructing Biological Pathways by a Two-Step Counting Approach
  72. Approximate Tolerance Limits Under Log-Location-Scale Regression Models in the Presence of Censoring
  73. Closed Form Prediction Intervals Applied for Disease Counts
  74. The monotone boundary property and the full coverage property of confidence intervals for a binomial proportion
  75. Comparison of control charts for low defective rate
  76. Increasing MicroRNA target prediction confidence by the relative R2 method
  77. Tolerance Intervals With Improved Coverage Probabilities for Binomial and Poisson Variables
  78. Improved variance estimators for one- and two-parameter models of nucleotide substitution
  79. Confidence intervals for the mean of a normal distribution with restricted parameter space
  80. Coverage probability of prediction intervals for discrete random variables
  81. Exact average coverage probabilities and confidence coefficients of confidence intervals for discrete distributions
  82. Exact confidence coefficients of simultaneous confidence intervals for multinomial proportions
  83. Ranking responses in multiple-choice questions
  84. ϵ-Admissible Estimators for Normal and Poisson Means
  85. Estimation of the Probability of Passing the USP Dissolution Test
  86. Modified p-values for one-sided testing in restricted parameter spaces
  87. Modified p-Value of Two-Sided Test for Normal Distribution with Restricted Parameter Space
  88. Improved confidence estimators for confidence sets of location parameters
  89. Improved estimation of accuracy in simple hypothesis versus simple alternative testing
  90. Improved confidence estimators for the usual one-sided confidence intervals for the ratio of two normal variances
  91. Admissibility of Confidence Estimators in the Regression Model
  92. The problem of low counts in a signal plus noise model
  93. Brown's paradox in the estimated confidence approach
  94. Estimated confidence under ancillary statistic everywhere-valid constraint
  95. Admissibility of the constant-coverage probability estimator for estimating the coverage function of certain confidence interval